ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

Senior Associate Scientist of Cellular Analytical Development at Strand Therapeutics - ApplyBlast

Senior Associate Scientist of Cellular Analytical Development

Strand Therapeutics

1 month ago

Boston, Massachusetts, United States

Onsite

Full Time

Senior

0 applicants

View Job Listing

Apply to 100+ jobs

About this role

Strand Therapeutics is seeking a Senior Associate Scientist of Cellular Analytical Development to independently execute cell-based experiments and develop analytical methods for mRNA and LNP therapeutics. The role involves supporting screening, optimization, and scale-up efforts while collaborating with external collaborators and utilizing statistical tools for data analysis. This position requires a strategic thinker with strong laboratory skills and the ability to thrive in a dynamic, early-stage biotechnology environment.

Responsibilities

Develop and execute cell-based mRNA and LNP analytical methods
Transfer cell-based methods to external collaborators
Analyze data using statistical tools to draw independent conclusions

Skills

Qualifications

B.S. or advanced degree in Biology, Biochemistry, Molecular Biology, Chemistry, Chemical Engineering or other relevant scientific discipline

About Strand Therapeutics

strandtx.com

Headquarters

Boston, Massachusetts, United States

Company Size

51-200 employees

Founded

2017

View Profile

Strand Therapeutics is a clinical-stage biotechnology company developing programmable mRNA therapeutics for solid tumors, blood cancers, and autoimmune diseases. The company's platform addresses core challenges in genetic medicine—targeting, safety, and potency—through proprietary technologies including SignalPath LNPs for tissue-specific delivery, SignalLock RNA for microRNA-based mRNA encryption, and SignalScript RNA for enhanced potency and durability. Its pipeline includes STX-001 for solid tumors, STX-003 for systemic tumor delivery, and STX-005, a pioneering in vivo CAR-T approach for autoimmune diseases and blood cancers.